Definition, Classification, Diagnosis and Differential Diagnosis of
                    Diabetes Mellitus: Update 2023

Stefan Pleus; Andrea Tytko; Rüdiger Landgraf; Lutz Heinemann; Christoph Werner; Dirk Müller-Wieland; Anette-Gabriele Ziegler; Ulrich A. Müller; Guido Freckmann; Helmut Kleinwechter; Erwin Schleicher; Matthias Nauck; Astrid Petersmann

doi:10.1055/a-2166-6643

Experimental and Clinical Endocrinology & Diabetes, Inhaltsverzeichnis

Exp Clin Endocrinol Diabetes 2024; 132(03): 112-124
DOI: 10.1055/a-2166-6643

German Diabetes Associaton: Clinical Practice Guidelines

Definition, Classification, Diagnosis and Differential Diagnosis of Diabetes Mellitus: Update 2023

Stefan Pleus^†

¹Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany

,

Andrea Tytko^†

²Die Diabetespraxis Northeim, Northeim, Germany

,

Rüdiger Landgraf

³German Diabetes Foundation (DDS) Düsseldorf, Munich, Germany

,

Lutz Heinemann

⁴Science-Consulting in Diabetes GmbH, Düsseldorf, Germany

,

Christoph Werner

⁵Department of Internal Medicine III, University Hospital Jena, Jena, Germany

,

Dirk Müller-Wieland

⁶Department of Internal Medicine I, RWTH Aachen University, Aachen, Germany

,

Anette-Gabriele Ziegler

⁷Institute of Diabetes Research, Helmholtz Zentrum Munich, Munich-Neuherberg, Germany

,

Ulrich A. Müller

⁸Practice for Endocrinology and Diabetology, Dr. Kielstein Ambulante Medizinische Versorgung GmbH, Jena, Germany

,

Guido Freckmann

¹Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany

,

Helmut Kleinwechter

⁹diabetologikum kiel, Kiel, Germany

,

Erwin Schleicher

¹⁰Institute of Clinical Chemistry and Pathobiochemistry – Central Laboratory, University Hospital Tübingen, Tübingen, Germany

¹¹German Center for Diabetes Research (DZD) Munich-Neuherberg, Munich-Neuherberg, Germany

,

Matthias Nauck

¹²Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany

¹³DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, University Medicine, Greifswald, Germany

,

Astrid Petersmann

¹²Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany

¹⁴Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Oldenburg, Oldenburg, Germany

References
1 Akturk HK, Kahramangil D, Sarwal A. et al. Immune checkpoint inhibitorinduced Type 1 diabetes: a systematic review and meta-analysis. Diabet Med 2019; 36: 1075-1081
2 Chen X, Affinati AH, Lee Y. et al. Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes. Diabetes Care 2022; 45: 1170-1176
3 The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358: 1991-2002
4 Gemeinsamer Bundesausschuss (G-BA). Im Internet: https://www.g-ba.de/themen/methodenbewertung/ambulant/frueherkennung-krankheiten/erwachsene/schwangerschaft-mutterschaft/
5 Deutsche Diabetes Gesellschaft und Deutsche Gesellschaft für Gynäkologie und Geburtshilfe. Hrsg. S3-Leitlinie Gestationsdiabetes mellitus (GDM), Diagnostik, Therapie und Nachsorge. AWMF-Registernummer: 057-008. 2018. Im Internet (Stand: 14.08.2019): 2. Auflage: https://www.awmf.org/uploads/tx_szleitlinien/057-008l_S3_Gestationsdiabetes-mellitus-GDM-Diagnostik-Therapie-Nachsorge_2019-06.pdf
6 Kleinwechter H. Gestational diabetes mellitus. update 2022. MMW Fortschr Med 2022; 164: 29-34
7 ElSayed NA, Aleppo G, Aroda VR. et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46: S19-S40
8 World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. 2006
9 International Diabetes Federation. IDF Diabetes Atlas 10th Edition. Im Internet: https://diabetesatlas.org/data/en/
10 Crowther CC, Samuel D, McCowan LME. et al. Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes. N Engl J Med 2022; 387: 587-598
11 Pleus S, Heinemann L, Freckmann G. et al. Glukosemessung in der Diabetesdiagnostik und -therapie: Laboratoriumsmedizinische Untersuchung inkl. Patientennaher Sofortdiagnostik, Blutglukoseselbstmesung und kontinuierliches Glukosemonitoring. Diabetol Stoffwechs 2022; 17: 52-60
12 Freckmann G, Heinemann L, Pleus S. et al. Messqualität bei der Glukosemessung im Rahmen der Diabetesdiagnose und -therapie in Deutschland. Dtsch Med Wochenschr 2022; 147: 413-417
13 Richtlinie der Bundesärztekammer zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen. Deutsches Ärzteblatt 2023;
14 Fischer MM, Hannemann A, Winter T. et al. Relative Efficacy of Different Strategies for Inhibition of in Vitro Glycolysis. Clin Chem 2021; 67: 1032-1034
15 Heinemann L, Adamczewski H. Neumann Ch et al. Gemeinsames Positionspapier der Kommission Labordiagnostik in der Diabetologie der DDG und DGKL und der Kommission Apotheker in der Diabetologie BAK/DDG zur Herstellung einer oGTT-Lösung für die Diagnose eines Diabetes einschließlich eines Gestationsdiabetes. Diabetol Stoffwechs 2020; 15: 470-471
16 Krüger M, Heinemann L. Verfügbarkeit von Fertiglösungen für den oGTT: ein Update. Diabetes Stoffw. Herz 2023; 23: 90-91
17 Heil W, Jachtmann A, Rick W. Zur Reproduzierbarkeit der Ergebnisse des oralen Glucose-Toleranz-Tests. Lab Med 1990; 14: 440-444
18 Landgraf R. HbA1c in der Diabetes-Diagnostik. Der Goldstandard? Diabetes aktuell 2021; 19: 22-29
19 Heinemann L, Freckmann G. Quality of HbA1c Measurement in the Practice: The German Perspective. J Diabetes Sci Technol 2015; 9: 687-695
20 Heinemann L, Kaiser P, Freckmann G. et al. Higher HbA1c Measurement Quality Standards are Needed for Follow-Up and Diagnosis: Experience and Analyses from Germany. Horm Metab Res 2018; 50: 728-734
21 Richtlinie der Bundesärztekammer zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen. Deutsches Ärzteblatt 2019;
22 Pani LN, Korenda L, Meigs JB. et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care. 2008 31. 1991-1996
23 Merker L, Ebert T, Guthoff M. et al. Nephropathie bei Diabetes. Diabetol Stoffwechs 2022; 17: S327-S331
24 Baker L, Maley JH, Arévalo A. et al. Real-world characterization of blood glucose control and insulin use in the intensive care unit. Sci Rep 2020; 10: 10718
25 Pieri M, Paleari R, Dalfrá MG. et al. Reference intervals for HbA1c partitioned for gender and age: a multicenter study. Acta Diabetol 2016; 53: 1053-1056
26 Roth J, Müller N, Lehmann T. et al. HbA1c and Age in Non-Diabetic Subjects: An Ignored Association?. Exp Clin Endocrinol Diabetes 2016; 124: 637-642
27 Masuch A, Friedrich N, Roth J. et al. Preventing misdiagnosis of diabetes in the elderly: age-dependent HbA1c reference intervals derived from two population-based study cohorts. BMC Endocr Disord 2019; 19: 20
28 Ma Q, Liu H, Xiang G. et al. Association between glycated hemoglobin A1c levels with age and gender in Chinese adults with no prior diagnosis of diabetes mellitus. Biomed Rep 2016; 4: 737-740
29 Wu L, Lin H, Gao J. et al. Effect of age on the diagnostic efficiency of HbA1c for diabetes in a Chinese middle-aged and elderly population: The Shanghai Changfeng Study. PLoS One 2017; 12: e0184607
30 Qi J, Su Y, Song Q. et al. Reconsidering the HbA1c Cutoff for Diabetes Diagnosis Based on a Large Chinese Cohort. Exp Clin Endocrinol Diabetes 2021; 129: 86-92
31 Ozarda Y, Sikaris K, Streichert T. et al. Distinguishing reference intervals and clinical decision limits – A review by the IFCC Committee on Reference Intervals and Decision Limits. Crit Rev Clin Lab Sci 2018; 55: 420-431
32 The DECODE-study group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 1999; 42: 647-654
33 vanʼt Riet E, Alssema M, Rijkelijkhuizen JM. et al. Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study. Diabetes Care 2010; 33: 61-66
34 Peter A, Fritsche A, Stefan N. et al. Diagnostic value of hemoglobin A1c for type 2 diabetes mellitus in a population at risk. Exp Clin Endocrinol Diabetes 2011; 119: 234-237
35 Keutmann S, Zylla S, Dahl M. et al. Measurement Uncertainty Impacts Diagnosis of Diabetes Mellitus: Reliable Minimal Difference of Plasma Glucose Results. Diabetes Ther 2020; 11: 293-303
36 Taboulet P, Deconinck N, Thurel A. et al. Correlation between urine ketones (acetoacetate) and capillary blood ketones (3-beta-hydroxybutyrate) in hyperglycaemic patients. Diabetes Metab 2007; 33: 135-139
37 Glaser N, Fritsch M, Priyambada L. et al. ISPAD clinical practice consensus guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes 2022; 23: 835-856
38 Thaler M, Roos M, Petersmann A. et al. Auto-Antikörper-Diagnostik in der Diabetologie – Aktueller Stand der Analytik und klinische Anwendung in Deutschland. Diabetol Stoffwechs 2022; 17: 382-388
39 Ahlqvist E, Storm P, Käräjämäki A. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6: 361-369
40 Wagner R, Heni M, Tabák AG. et al. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med 2021; 27: 49-57
41 Herder C, Roden M. A novel diabetes typology: towards precision diabetology from pathogenesis to treatment. Diabetologia 2022; 65: 1770-1781
42 Hörber S, Achenbach P, Schleicher E. et al. Harmonization of immunoassays for biomarkers in diabetes mellitus. Biotechnol Adv 2020; 39: 107359
43 Lampasona V, Pittman DL, William AJ. et al. Islet Autoantibody Standardization Program 2018 Workshop: Interlaboratory Comparison of Glutamic Acid Decarboxylase Autoantibody Assay Performance. Clin Chem 2019; 65: 1141-1152
44 Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 2013; 30: 803-817
45 Fritsche A, Heni M, Peter A. et al. Considering Insulin Secretory Capacity as Measured by a Fasting C-Peptide/Glucose Ratio in Selecting Glucose-Lowering Medications. Exp Clin Endocrinol Diabetes 2022; 130: 200-204
46 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
47 Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495
48 Zavaroni I, Deferrari G, Lugari R. et al. Renal metabolism of C-peptide in man. J Clin Endocrinol Metab 1987; 65: 494-498
49 Bonser AM, Garcia-Webb P. C-peptide measurement: methods and clinical utility. Crit Rev Clin Lab Sci 1984; 19: 297-352
50 DʼElia JA, Mulla CH, Liu J. et al. Variations in glucose/C-peptide ratio in patients with type 2 diabetes associated with renal function. Diabetes Res Clin Pract 2019; 150: 1-7
51 Nationale Versorgungsleitlinie Typ-2-Diabetes. Teilpublikation der Langfassung Version 1. 2021. AWMF Register Nr. nvl-001. Im Internet: www.leitlinien.de/themen/diabetes
52 Holt RIG, DeVries JH, Hess-Fischl A. et al. The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2021; 44: 2589-2625
53 Besser REJ, Bell KJ, Couper JJ. et al. ISPAD clinical practice consensus guidelines 2022: Stages of type 1 diabetes in children and adolescents https://www.ispad.org/resource/resmgr/consensus_guidelines_2018_/guidelines2022/ch._2_pediatric_diabetes_-_2.pdf
54 Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. Lancet 2016; 387: 2340-2348
55 Ziegler AG, Rewers M, Simell O. et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309: 2473-2479
56 Sims EK, Besser REJ, Dayan C. et al. Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes 2022; 71: 610-623
57 Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol 2017; 13: 674-686
58 Leslie RD, Evans-Molina C, Freund-Brown J. et al. Adult-Onset Type 1 Diabetes: Current Understanding and Challenges. Diabetes Care 2021; 44: 2449-2456
59 Harding JL, Wander PL, Zhang X. et al. The Incidence of Adult-Onset Type 1 Diabetes: A Systematic Review From 32 Countries and Regions. Diabetes Care 2022; 45: 994-1006
60 Badenhoop K. MODY und andere monogenetische Diabetesformen. Diabetologe 2017; 13: 453-463
61 Bojunga J, Schlereth F. Type 3c diabetes mellitus-prevalence, diagnosis, special aspects of treatment. Diabetologe 2018; 14: 269-277
62 Kufeldt J, Kovarova M, Adolph M. et al. Prevalence and Distribution of Diabetes Mellitus in a Maximum Care Hospital: Urgent Need for HbA1c-Screening. Exp Clin Endocrinol Diabetes 2018; 126: 123-129
63 Ahuja V, Aronen P, Pramodkumar TA. et al. Accuracy of 1-hour plasma glucose during the oral glucose tolerance test in diagnosis of type 2 diabetes in adumts: A meta-analsis. Diabetes Care 2021; 44: 1062-1069
64 Zaharia OP, Strassburger K, Strom A. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7: 684-694
65 Achenbach P, Hippich M, Zapardiel-Gonzalo J. et al. A classification and regression tree analysis identifies subgroups of childhood type 1 diabetes. EBioMedicine 2022; 82: 104118
66 Broome DT, Pantalone KM, Kashyap SR. et al. Approach to the Patient with MODY-Monogenic Diabetes. J Clin Endocrinol Metab 2021; 106: 237-250